Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by davikingon Feb 18, 2010 12:41pm
300 Views
Post# 16795989

Interesting days

Interesting daysHaving followed this stock for a few years, it amazes me how we got this far and then are stalled.
Waiting for the approval of this funding/trial is difficult at best. Without the funding, the company was going nowhere. As mentioned, someone didn't like the deal. Long-time shareholders are being diluted by 2/3 if and when the deal goes through and presumably, the mutual funds buy up all their warrants.
Do they know more than we? Probably and so that is why they are in the hunt for more.
This trial is going to be very interesting and we'll see, imo, by the end of the year, some results and indications whether or not this is a successful treatment.
They will be testing against a "control" of the most difficult/sickest patients. Indications of success will be available within 28 days and after months?/year, they will release an "interim" report. That will be another milestone, after funding, initiating the trial, which will determine the share price.
This "treatment" is not for all sepsis patients! There are many ways to "get" sepsis.
Sepsis has come to the forefront in recent years and maybe the "cause" of complications from surgery, that arises. Does Toraymyxin work on those patients? Don't know.

Interesting scenario about the price nowadays. I suppose that I would like .40 shares but have enough already. I'm thinking that the mutual funds involved are pretty astute but then, some of them have had shares in this company for years and that hasn't worked out so well.
Bullboard Posts